MEDFORD, NY and RIO DE JANEIRO, BRAZIL--(Marketwire - October 02, 2008) - Chembio Diagnostics, Inc. (OTCBB: CEMI) ("Chembio" or the "Company") and the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ") today announced the completion of a technology transfer supply and license agreement for Chembio's DPP® HIV 1-2 rapid test for use with oral fluid or whole blood samples. This product has been developed by Chembio with its patented Dual Path Platform (DPP®) technology. As previously announced in January, Chembio and FIOCRUZ also executed similar agreements for DPP® rapid tests for Leishmania and Leptospirosis, and a third agreement for a multiplex DPP® test for the confirmation of HIV-1 that could be performed at the point of care. FIOCRUZ, which is affiliated with the Brazilian Ministry of Health, is its leading supplier for therapeutics, vaccines and diagnostic tests.
